Pharmaceutical Preparations · DE · CIK 1401667
Develops and commercializes innovative cancer treatments, currently marketing NERLYNX for HER2-positive breast cancer
Comparable business profile · signals at a glance
In the 90 days to Jan 7, 2026: 4 sold $419K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 7, 2026 | Auerbach Alan HPresident and CEO | Sell | 18,012 | $5.88 | $106K |
| Jan 7, 2026 | Nougues Maximo FChief Financial Officer | Sell | 6,405 | $5.88 | $38K |
| Jan 7, 2026 | Hunt Douglas MSee Remarks | Sell | 5,014 | $5.88 | $29K |
| Jan 6, 2026 | Auerbach Alan HPresident and CEO | Sell | 16,938 | $5.84 | $99K |
| Jan 6, 2026 | Nougues Maximo FChief Financial Officer | Sell | 4,540 | $5.84 | $27K |
| Jan 6, 2026 | Hunt Douglas MSee Remarks | Sell | 3,973 | $5.84 | $23K |
| Nov 11, 2025 | Miller Michael PatrickDirector | Sell | 20,000 | $4.86 | $97K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.